CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.54
-0.36 (-4.04%)
May 9, 2025, 11:28 AM - Market open
CervoMed Employees
CervoMed had 15 employees as of December 31, 2024. The number of employees increased by 7 or 87.50% compared to the previous year.
Employees
15
Change (1Y)
7
Growth (1Y)
87.50%
Revenue / Employee
$649,198
Profits / Employee
-$1,086,046
Market Cap
74.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRVO News
- 5 weeks ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 6 weeks ago - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - GlobeNewsWire
- 6 weeks ago - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
- 2 months ago - CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewsWire
- 5 months ago - CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Benzinga
- 5 months ago - CervoMed's stock craters 77% after failed trial of treatment for rare brain disease - Market Watch